Citation:Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al 2012

Citation

Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012 Jul 12;367(2):107-14 Available from: http://www.ncbi.nlm.nih.gov/pubmed/22663011.

Critical appraisals

• Assign a critical appraisal

Critical appraisal link	Clinical question	Assigned to	Status
Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al 2012	Does systemic drug therapy improve progression-free, overall survival in unresectable stage III and stage IV melanoma?	Meghna Kakani	completed
Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al 2012 2	Does systemic drug therapy improve progression-free, overall survival in unresectable stage III and stage IV melanoma?	Cecilia Taing	completed

Compare quality appraisals for each clinical question

• [[Clinical question:Does systemic drug therapy improve progression free, overall survival in Stage 3C unresectable and stage 4 melanoma?|]] (compare critical appraisals)
• [[Clinical question:Does systemic drug therapy improve progression free, overall survival in Stage 3C unresectable and stage 4 melanoma?|]] (compare critical appraisals)

Cited by

1. Targeted therapies for melanoma